Wall Street analysts predict that Anavex Life Sciences Corp. (NASDAQ:AVXL) will post earnings of ($0.10) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Anavex Life Sciences Corp.’s earnings. Anavex Life Sciences Corp. reported earnings of ($0.18) per share in the same quarter last year, which would indicate a positive year over year growth rate of 44.4%. The firm is scheduled to report its next quarterly earnings results on Monday, December 11th.

On average, analysts expect that Anavex Life Sciences Corp. will report full-year earnings of ($0.36) per share for the current fiscal year. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that cover Anavex Life Sciences Corp..

Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09).

Several research firms recently issued reports on AVXL. Maxim Group set a $15.00 price target on shares of Anavex Life Sciences Corp. and gave the stock a “buy” rating in a report on Thursday, October 12th. Noble Financial reissued a “buy” rating and set a $15.00 price target on shares of Anavex Life Sciences Corp. in a report on Friday, September 29th. ValuEngine cut shares of Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a report on Thursday, September 28th. Finally, Zacks Investment Research raised shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Tuesday, September 26th.

Shares of Anavex Life Sciences Corp. (NASDAQ AVXL) traded down 3.85% during trading on Tuesday, hitting $4.75. The company had a trading volume of 234,751 shares. The firm’s market capitalization is $200.32 million. The stock’s 50-day moving average is $4.33 and its 200 day moving average is $4.33. Anavex Life Sciences Corp. has a 52-week low of $2.76 and a 52-week high of $6.64.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Anavex Life Sciences Corp. by 8.9% in the second quarter. Vanguard Group Inc. now owns 1,617,757 shares of the biotechnology company’s stock valued at $8,606,000 after buying an additional 132,076 shares in the last quarter. State Street Corp increased its holdings in Anavex Life Sciences Corp. by 15.2% in the second quarter. State Street Corp now owns 603,326 shares of the biotechnology company’s stock valued at $3,210,000 after buying an additional 79,516 shares in the last quarter. Northern Trust Corp increased its holdings in Anavex Life Sciences Corp. by 16.0% in the second quarter. Northern Trust Corp now owns 429,073 shares of the biotechnology company’s stock valued at $2,282,000 after buying an additional 59,069 shares in the last quarter. Geode Capital Management LLC increased its holdings in Anavex Life Sciences Corp. by 16.8% in the first quarter. Geode Capital Management LLC now owns 276,974 shares of the biotechnology company’s stock valued at $1,589,000 after buying an additional 39,934 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Anavex Life Sciences Corp. by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 111,880 shares of the biotechnology company’s stock valued at $642,000 after buying an additional 5,826 shares in the last quarter. 24.24% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Analysts Expect Anavex Life Sciences Corp. (AVXL) Will Announce Earnings of -$0.10 Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/24/analysts-expect-anavex-life-sciences-corp-avxl-will-announce-earnings-of-0-10-per-share.html.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get a free copy of the Zacks research report on Anavex Life Sciences Corp. (AVXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.